Pilot study of tranilast for cardiomyopathy of muscular dystrophy

Pilot study of tranilast for cardiomyopathy of muscular dystrophy - Pilot study of tranilast for cardiomyopathy of muscular dystrophy

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000020580

Enrollment

Registered

2016-01-20

Start date

2016-01-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

muscular dystrophy

Interventions

Tranilast 300mg/day for three months (oral intake)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: patients with muscular dystrophy LVDd >=50% LVFS < 20%

Exclusion criteria

Exclusion criteria: Patients with severe hepatic dysfunction, renal dysfunction, eosinophilia or any other conditions unsuitable for taking tranilast

Design outcomes

Primary

Measure	Time frame
Left ventricular fractional shortening, Left ventricular dilated dimension (before, 1 month, 3 months)	—

Secondary

Measure	Time frame
Brain natriuretic peptide, cardiac troponin T, cardiac events (before, 1 month, 3 months)	—

Countries

Japan

Contacts

Public ContactTsuhoshi Matsumura

National Hospital Organization Toneyama National Hospital Neurology

tmatsumura-toneyama@umin.org06-6853-2001

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026